S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:ZGNX

Zogenix Stock Forecast, Price & News

$18.64
-0.33 (-1.74 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.62
Now: $18.64
$19.23
50-Day Range
$18.97
MA: $20.62
$22.23
52-Week Range
$16.65
Now: $18.64
$57.22
Volume1.19 million shs
Average Volume1.06 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). Zogenix, Inc. has collaboration with Tevard Biosciences to advance novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Zogenix logo

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

166th out of 1,480 stocks

Pharmaceutical Preparations Industry

81st out of 612 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300
Employees141

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,758.48%

Miscellaneous

Market Cap$1.04 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$18.64
-0.33 (-1.74 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock been impacted by COVID-19?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZGNX stock has decreased by 17.8% and is now trading at $18.64.
View which stocks have been most impacted by COVID-19
.

Is Zogenix a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zogenix stock.
View analyst ratings for Zogenix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zogenix?

Wall Street analysts have given Zogenix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zogenix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) issued its earnings results on Monday, November, 9th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.01) by $0.07. The business had revenue of $2.86 million for the quarter, compared to analysts' expectations of $2.35 million. Zogenix had a negative net margin of 8,758.48% and a negative return on equity of 53.91%. Zogenix's revenue for the quarter was up 354.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($6.75) EPS.
View Zogenix's earnings history
.

What price target have analysts set for ZGNX?

10 brokers have issued 1 year price objectives for Zogenix's stock. Their forecasts range from $27.00 to $78.00. On average, they expect Zogenix's share price to reach $53.29 in the next twelve months. This suggests a possible upside of 185.9% from the stock's current price.
View analysts' price targets for Zogenix
or view Wall Street analyst' top-rated stocks.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), (CGC), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 62, Pay $867.95k)
  • Mr. Michael P. Smith, Exec. VP, CFO & Treasurer (Age 53, Pay $573.34k)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 59, Pay $582.08k)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 57, Pay $568.5k)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer (Age 54, Pay $541.24k)
  • Mr. Jeff D. Durflinger, VP of Technical Operations & Product Supply (Age 60)
  • Ms. Shawnte M. Mitchell, Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Melinda Baker, Sr. Director of Corp. Communications
  • Mr. Bret E. Megargel, VP of Corp. Devel. (Age 52)
  • Mr. Stephen H. Jenner, VP of Marketing (Age 53)

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by a variety of institutional and retail investors. Top institutional investors include First Midwest Bank Trust Division (0.02%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Zogenix
or view top insider-selling stocks.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $18.64.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.04 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 141 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.